Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 6, 2026
Whitehawk Therapeutics, Inc. (WHWK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $16.6 million. Free cash flow was -$14.5 million.
Revenue
$0
Net income
$-16.64M
+68.4% vs year-ago quarter
Operating cash flow
$-14.53M
+72.6% vs year-ago quarter
Free cash flow
$-14.53M
+72.6% vs year-ago quarter
EPS
$-0.20
+73.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
57.01M
+21.0% vs year-ago quarter
Net cash
$145.70M
Q4 FY2025
Operating margin
-213.0%
Q1 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- WHWK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Morristown, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422142
- Former names
- Aadi Bioscience, Inc. (until Mar 18, 2025); Aerpio Pharmaceuticals, Inc. (until Aug 23, 2021); ZETA ACQUISITION CORP II (until Mar 13, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$18.1M | -$23.5M | -$24.9M | -$19.5M | -$54.7M |
| Net income | -$16.6M | -$22.2M | -$23.3M | -$17.7M | -$52.6M |
| Diluted EPS | -$0.20 | -$0.32 | -$0.35 | -$0.26 | -$0.76 |
| Operating cash flow | -$14.5M | -$22.2M | -$17.2M | -$15.4M | -$53.0M |
| Free cash flow | -$14.5M | -$22.2M | -$17.2M | -$15.4M | -$53.0M |
| Total assets | $194.0M | $127.2M | $150.8M | $167.0M | $180.8M |
| Total liabilities | $11.1M | $11.1M | $14.5M | $9.8M | $8.8M |
| Stockholders' equity | $182.9M | $116.2M | $136.3M | $157.2M | $172.1M |
| Cash and investments | $190.0M | $123.0M | $145.7M | $162.6M | $177.2M |
| Total debt | — | — | $0 | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 13, 2026 | May 12, 2026 |
All 671 Whitehawk Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.